27.44
1.61%
-0.45
After Hours:
26.74
-0.70
-2.55%
Celldex Therapeutics Inc (CLDX) Stock Split History
Celldex Therapeutics Inc has split its stock 3 times since its initial public offering (IPO). The first stock split occurred on March 07, 2008 with the ratio of 1-for-12, meaning that for 12 shares of CLDX owned pre-split, shareholders then owned 1 share. 2 more splits have been implemented since then. The most recent stock split took place on February 11, 2019 on a 1-for-15 basis.
These splits have increased CLDX stock's liquidity and made it more appealing to a larger group of investors. However, it's important to remember that these actions only change the number of shares and the price per share with no impact on Celldex Therapeutics Inc's total market capitalization.
For more detailed information of Celldex Therapeutics Inc's stock splits, view the table below:
These splits have increased CLDX stock's liquidity and made it more appealing to a larger group of investors. However, it's important to remember that these actions only change the number of shares and the price per share with no impact on Celldex Therapeutics Inc's total market capitalization.
For more detailed information of Celldex Therapeutics Inc's stock splits, view the table below:
CLDX stock split list
Date | Split Ratio |
---|---|
2019-02-11 | 1 - for - 15 |
2008-03-10 | 1 - for - 12 |
2008-03-07 | 1 - for - 12 |
Will Celldex Therapeutics Inc Stock Split in 2024?
The answer will depend on the decisions of the company's managers and market volatility. Celldex Therapeutics Inc has not made an official announcement regarding whether it will enact a stock split or reverse stock split, but it has a history of doing so when CLDX stock prices become too high or too low for retail investors. Therefore, the ultimate decisions will certainly be made by Celldex Therapeutics Inc's board of directors. Typically, no action is taken until its price per share reaches a specific threshold.
Stock Splits of Industry Leaders
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):